Natco Pharma’s marketing partner BPI obtains FDA approval for new drug

By Nikita Chaurasia  Date: 2021-03-10

Natco Pharma’s marketing partner BPI obtains FDA approval for new drug

Breckenridge Pharmaceutical Inc. (BPI), a marketing partner of Natco Pharma, has reportedly received U.S. Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application of Everolimus drug tablets.

The drug is basically a generic version of Afinitor and is primarily used for breast cancer treatment, as well as for treating other types of cancer. Sources confirmed that BPI is planning to launch tablets of 7.5 mg, 5 mg, and 2.5 mg strengths in the upcoming weeks.

The company will reportedly launch its 10 mg strength drugs after a licensing agreement and settlement with the owner of the Afinitor brand. A representative from Natco Pharma commented that the launch will be announced at a later date.

For those unaware, Breckenridge Pharmaceutical Inc. is a subsidiary of Japan-based Towa Pharmaceutical Co. Ltd. The company is headquartered in Berlin, Connecticut, and manufactures, distributes as well as markets over 82 pharmaceutical drugs in the U.S.

It has more than 40 Abbreviated New Drug Applications (ANDA) approved by the Food and Drug Administration and manufactures drugs in several categories including capsules, tablets, liquids, ophthalmics, transdermal patches, powders, nasal sprays, and injectable products.

BPI has partnered with manufacturers from across the world and aims to provide generic pharmaceuticals that are affordable and cost-effective to U.S. patients.

Recently, another Hyderabad-based drug maker, MSN Group, which also has a marketing partnership with BPI, announced that it had received final approval from USDA for its ANDA for Asenapine Sublingual Tablets.

MSN had earlier received final approval for 10 mg and 2.5 mg strengths of the same drug. The product will be launched by its marketing partner Breckenridge Pharmaceutical. The approved product is a generic version of Saphris and is employed for the treatment of bipolar disorder and schizophrenia.

According to MSN, Asenapine had recorded annual sales of USD 239 million during the year ending in September 2020.

Source Credits –

https://www.thehindu.com/business/natco-pharma-marketing-partner-bpi-gets-usfda-nod-for-anti-cancer-drug/article34022425.ece

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...